Administration of Eurotium cristatum improved glucose intolerance and dyslipidemia in obese mice, indicating modulation of gut microbiota and short-chain fatty acids production.
Key Points
This study aims to explore the effects of Eurotium cristatum on metabolic dysfunction in obese mice.
8-week administration of Eurotium cristatum at three doses (104, 106, and 108 CFU/mL).
Assessment of metabolic abnormalities caused by high-fat diet (HFD).
Measurement of intestinal gluconeogenesis pathway activation and gut microbiota composition.
Eurotium cristatum significantly reduced glucose intolerance and dyslipidemia in obese mice.
Treatment increased levels of short-chain fatty acids and activated key enzymes in gluconeogenesis.
Administration led to a lower Firmicutes/Bacteroidetes ratio and enrichment of beneficial bacteria.